Zoomedia Blog

Last week, I attended the Epilepsy Pipeline Update conference, provided by our client the Epilepsy Therapy Project. The Epilepsy Therapy Project exists to overcome the barriers to successful translation of promising new research insights and to make new therapies a reality for patients...

Tags: Patient Strategy, Clinical Strategy, Epilepsy Therapy Project

Zoomedia recently had the privilege to spend a day with the Multiple Myeloma Research Foundation discussing challenges and strategies to help the organization advance its mission to fund research and bring patients to the center of the drug development process.

Tags: Patient Strategy, MMRF

Wait, hold onto your tux!! Now that the Oscars are over why not put your tux to better use at the ALF Salute to Excellence Awards Gala, the annual black tie event honoring those who have made an outstanding contribution to biotechnology and medical innovation. The event has been held annually for ten years and to date has raised more than $3 million dollars. The honorees this year include Hollings C. Renton, Chairman, President and Chief Executive Officer, Onyx Pharmaceuticals, Inc, Frank McCormick, PhD, FRS, Co-Founder of Onyx Pharmaceuticals, Inc., Samuel So, MD, FACS, Director, Asian Liver Center, Director, Liver Cancer Program, The Lui Hac Minh Professor of Surgery, Stanford University School of Medicine with special recognition going to Mark G. Edwards, Managing Director of Recombinant Capital, Inc.

Tags: Patient Strategy

Many of our clients have asked us recently about “Web 2.0” technologies. Pharma DTC websites are beginning to see lively discussion around this topic and the technological advances behind the terminology are significant. Web 2.0, and all that the label stands for, indicates a major directional shift in online communication between all the stakeholders involved in DTC and DTP promotion. There is a significant patient empowerment movement emerging fueled by Web 2.0 that biotech and pharma cannot afford to ignore. This month we will address the Health 2.0 movement, its associated Web 2.0 terminology and technologies, and weigh-in on the debate many Biotechnology and Pharmaceutical companies are having about how, or whether, to best use these technologies. This is a very new form of communication particularly as applied to DTC promotion. In coming months, we will be publishing a series of articles and newsletters around social networking as it relates to our highly-regulated industry and the Health 2.0 movement.

Tags: Patient Strategy, Global Strategy, Product Strategy, Transforming Technology, Web 2.0